I yield myself such time as I may consume. (Mr. DINGELL asked and was given permission to revise and extend his remarks.) Mr. Speaker, I rise in support of H.R. 4250, the Sunscreen Innovation Act. This legislation proves that this body can…
I yield myself such time as I may consume.
(Mr. DINGELL asked and was given permission to revise and extend his remarks.)
Mr. Speaker, I rise in support of H.R. 4250, the Sunscreen Innovation Act. This legislation proves that this body can work together, not only across the aisle but with the agencies under our jurisdiction and also with the industries concerned. This legislation has the support of everyone.
There is no opposition to it, and that includes the industry, it includes the
health people, it also includes the environmentalists, and it includes the administration. UV rays from the Sun are, it is understood, increasing the amount of melanoma amongst our people enormously--800 percent amongst young women, and 400 percent amongst young men over the past 40 years.
Sunscreens sold in the United States today do not offer the same level of protection as sunscreen sold in Europe, Canada, Australia, and other countries. In fact, the last over-the-counter sunscreen ingredient was approved by FDA in the 1990s. Some sunscreen ingredients have been waiting review by FDA for over a decade.
This is inexcusable, and it should not be permitted because FDA has taken so long to review these applications. It is clear that increased accountability is needed at the agency to ensure these pending sunscreen applications are reviewed in a timely and speedy manner.
I want to commend and congratulate my colleague, Mr. Whitfield, for his leadership and fine work on this, and also Chairman Upton for his outstanding work, and I want to congratulate my friends, Mr. Pallone and Mr. Waxman, for the good work which they have done on this legislation.
Indeed, the staffs on both sides of the committee have been remarkable in what it is they have done on this matter, and it is interesting to note that we have the strong support of the American Academy of Dermatology, the American Cancer Society Cancer Action Network, the Melanoma Research Alliance, the Environmental Working Group, and the Melanoma Research Foundation.
Mr. Speaker, I insert letters from those agencies into the Record.
American Academy of Dermatology
Association,
Washington, DC, July 21, 2014.
Hon. Ed Whitfield,
U.S. House of Representatives, Washington, DC.
Hon. John Dingell,
U.S. House of Representatives, Washington, DC.
Dear Representative Whitfield and Representative Dingell:
The American Academy of Dermatology Association (Academy),
which represents more than 13,000 dermatologists nationwide,
commends you for working together to amend H.R. 4250, the
Sunscreen Innovation Act, which would ensure that sunscreen
ingredients are reviewed by the U.S. Food and Drug
Administration (FDA) within a predictable timeframe. The
Academy applauds you for your work with stakeholders on this
legislation and is pleased to offer its support for the
Committee-passed amended bill, which has the potential to
reduce Americans' risk for skin cancer by ensuring that they
have access to the safest, most effective sunscreens
available.
Skin cancer is the most common cancer in the United States
and one in five Americans will develop skin cancer in their
lifetime. Dermatologists diagnose more than 3.5 million cases
and treat more than 2.2 million people with skin cancer every
year in the U.S. Research has shown that sunscreen helps
reduce the risk of skin cancer and is essential to protecting
the public from UV radiation. Proper use of sunscreen
combined with access to the safest, most effective
ingredients available will go a long way toward reducing
these statistics.
We applaud you for working together to amend this
legislation, which will ensure that sunscreen ingredients are
thoroughly and expeditiously reviewed in a timely manner. We
support allowing the Nonprescription Drugs Advisory Committee
(NDAC) to provide recommendations on sunscreen ingredients to
the FDA, and are pleased to see a provision under the amended
bill that would allow the Secretary to appoint members of
other federal advisory committees or outside consultants with
substantive expertise regarding sunscreen active ingredients
to the NDAC when sunscreen ingredients are reviewed. We are
also in favor of the provisions within the amended
legislative language that strengthen Congressional oversight
by requiring reporting of FDA's activities and progress in
the review of sunscreen ingredients.
We appreciate your continued leadership on this issue and
look forward to working with you in the fight against skin
cancer. If you have any questions or if we can provide any
additional information, please contact Christine O'Connor,
the Academy's Associate Director, Congressional Policy at
[email protected] or (202) 609-6330; or Niva Haynes, the
Academy's Manager, Congressional Policy at [email protected] or
(202) 712-2608.
Sincerely,
Brett M. Coldiron, MD, FAAD,
President, American Academy of
Dermatology Association.
I would like to observe that the staff has performed extraordinary work on this matter. I want to congratulate and thank Greg Sunstrum on my staff, as well as Taylor Booth, John Stone, Carly McWilliams, and Eric Flamm for their hard work on the legislation, and I want to recognize members of the PASS Coalition for their hard work and advocacy on behalf of this important issue.
Mr. Speaker, I reserve the balance of my time.
Mr. Speaker, I have no further requests for time, so if the gentleman, my good friend, Mr. Whitfield, is ready, I am prepared to yield back with the strong urging to my colleagues to support this bill--which is strongly bipartisan--unanimously brought forward to the Congress and which has the strong support of both industry, government, and health groups.
Mr. Speaker, I yield back the balance of my time.